Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck cancer, excluding thyroid

4519 - Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma


09 Sep 2017


Head and neck cancer, excluding thyroid


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Head and Neck Cancers


Wim Boxtel


Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374


W. Boxtel1, L.D. Locati2, S. Tooten1, E. Bos1, C. Bergamini2, A.C.H. van Engen-van Grunsven3, E. Boon1, E. Fiets4, S. Cavalieri2, G. Verhaegh5, J. Schalken5, L. Licitra2, C.M.L. Herpen1

Author affiliations

  • 1 Department Of Medical Oncology, Radboudumc, 6525AG - Nijmegen/NL
  • 2 Medical Oncology Unit/head And Neck Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano/IT
  • 3 Department Of Pathology, Radboudumc, 6525AG - Nijmegen/NL
  • 4 Department Of Medical Oncology, Medical Centre Leeuwarden, Leeuwarden/NL
  • 5 Laboratory Of Experimental Urology, Radboudumc, 6525AG - Nijmegen/NL


Abstract 4519


Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer, with a median disease-free survival (DFS) of less than 3 years. SDC is androgen receptor-positive (AR+) in 67-96% of cases. In incurable recurrent AR+ SDC androgen deprivation therapy (ADT) has an overall response rate of 18-50%. In this study, high-risk AR+ SDC pts were treated with adjuvant ADT to study the efficacy.


In this retrospective study, surgical resected pts who received adjuvant ADT for stage 4a/b AR+ SDC at the Radboudumc (Nijmegen, the Netherlands) or Istituto Nazionale dei Tumori (Milan, Italy) were collected. As control group, surgical resected pts diagnosed with stage 4a/b SDC between 1990-2014, who did not receive adjuvant ADT were collected by a search of the Dutch pathology database (PALGA). Pts were analyzed for DFS and overall survival (OS) by using Kaplan-Meier survival curves.


18 AR+ SDC pts (median age 64 years [range 32-80]) were treated with adjuvant ADT (Nijmegen n = 11; Milan n = 7) for a median duration of 10 months [range 2-31 months]. All pts had a nuclear AR-staining pattern in > 70% of the cells. They were treated with bicalutamide monotherapy (n = 10), a LHRH analog (n = 1) or a combination of these (n = 7). Treatment was well tolerated. 17/18 pts (94.4%) also received postoperative radiotherapy, of which 4 pts received concurrent chemoradiotherapy (22.2%). The control group consisted of 110 SDC pts (median age 70 years [range 44-100]). 103/110 pts (93.6%) received postoperative radiotherapy, of which 1 pt received concurrent chemoradiotherapy (0.9%). After a median follow-up of 22 months in the ADT-treated SDC pts and 25 months in the control SDC pts, the 3-year DFS was 53.6% and 34.2% (p = 0.137), the 3-year OS was 68.2% and 52.3% (p = 0.198), respectively. The median DFS and OS were not reached in the ADT-treated SDC pts and were 21 months and 46 months in the control SDC pts.


Adjuvant ADT in high-risk AR+ SDC pts did not lead to a significant increase in DFS or OS, but the number of treated pts was limited. Due to the rarity of the disease we could not perform a formal phase II study. Translational research to identify pts which may benefit from ADT is warranted.

Clinical trial identification

Legal entity responsible for the study

Carla M.L. van Herpen




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.